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Abstract
Background: Evidence on the association of leptin and adiponectin and smoking is limited and discordant. Leptin
and adiponectin represent the most abundant adipokines in human plasma that play crucial roles in the
pathophysiology of metabolic syndrome, atherosclerosis and insulin resistance. Leptin up-regulates the expression
of several pro-inflammatory cytokines and is increased upon weight gain. Adiponectin has been shown to possess
insulin sensitizing, anti -inflammatory and anti-atherogenic properties and is increased upon weight reduction. Our
aim was to assess the effects of smoking cessation on serum leptin and adiponectin levels.
Methods: We assessed the changes in serum leptin and adiponectin levels, serum CRP levels and BMI in apparently
healthy smokers after 3 and 6 months of abstinence from smoking. Successful cessation was confirmed by an
exhaled carbon monoxide measurement. 26 healthy non-smokers were recruited as controls.
Results: Among the sample group, 32 subjects had quitted smoking at 3 months and 29 subjects at 6 months.
Samples’ leptin increased significantly from baseline to three months (mean change 3.76 ng/ml [95 % CI 0.89, 6.64],
p =0.012) and then decreased significantly from three to six months of smoking cessation (mean change -4,29 ng/
ml [95 % CI −7.34, −6.64], p = 0.008). Samples’ adiponectin increased significantly from baseline to three months of
abstinence from smoking (mean change 2.34 [95 % CI −0.05, 4.73], p −0.05). BMI was significantly increased (mean
change 2.03 kg/m2 [95 % CI 1.60, 2.46], p <0.05), while CRP decreased significantly from baseline to 6 months of
smoking cessation (mean change −0.68 mg/dl [95 % CI −1.06, −0.30], p = 0.001).
Conclusions: Smoking quitters’ leptin levels appear to increase 3 months after smoking cessation and then
decrease from 3 to 6 months of abstinence from smoking. Adiponectin levels increase during the first trimester of
smoking cessation. The decrease in CRP levels indicates that the low grade inflammation observed in smokers is
gradually restored. The alterations of serum leptin and adiponectin after 6 months of smoking cessation suggest
the same but do not reach statistically significant levels. Weight gain and changes in fat distribution may attenuate
the beneficial effects of smoking cessation.
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Background
Smoking is a major atherosclerotic risk factor and is associ-
ated with the development of metabolic syndrome leading
to cardiovascular disease [1–3]. Among other harmful
effects, long term smoking is reported to increase inflam-
mation, lipid peroxidation, endothelial cell dysfunction and
insulin resistance [4–6]. Since it is evident that adiponectin
protects and leptin accelerates the development of athero-
sclerotic diseases we can speculate that these adipokines
may be the link between smoking and cardiovascular and
metabolic diseases.
Leptin and adiponectin are secreted by adipose tissue and
represent the most abundant adipokines in human plasma.
Since its cloning in 1994 [7], leptin has been acknowledged
as a major endocrine signal in the homeostatic control of
body weight [8]. Weight gain is associated with increased
circulating leptin levels while fasting reduces leptin levels
[9]. Beyond its metabolic functions, leptin is a pleiotropic* Correspondence: mariakryfti@gmail.com16th Respiratory Medicine Department, Sotiria General Hospital for Thoracic
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cytokine involved in the recruitment, activation and
survival of inflammatory cells [10]. On the other hand,
adiponectin, an adipocyte-derived protein, has been
shown to possess insulin sensitizing, anti-inflammatory
and anti-atherogenic properties [8, 11, 12]. Further-
more, adiponectin concentration can be upregulated
upon weight reduction [13].
Both cigarette smoking and obesity are accompanied by a
low grade subclinical chronic inflammation. Leptin and
adiponectin can be considered markers of subclinical in-
flammation with opposing effects and it is well appreciated
that plasma levels of C-reactive protein have a positive
correlation with plasma leptin and a negative correlation
with plasma adiponectin [14–16]. Despite the well known
inverse association between smoking and body weight,
there have been conflicting reports on the effects of smok-
ing on serum leptin and adiponectin levels [17–22].
The aim of this study is to examine the effects of




The patients included in our study were recruited from
the outpatient smoking cessation department of “Sotiria
General Chest Hospital”. Eligibility criteria included age
≥18 years, smoking of ≥15 cigarettes/day for ≥5 years, and
self-motivation for quitting. We excluded patients with a
history of diabetes mellitus, severe obesity or cachexia,
chronic alcohol abuse, acute infection such as respiratory
tract infection or COPD exacerbation one month prior to
the study, chronic inflammatory diseases such as asthma
or interstitial lung disease, collagen vascular disease or
disturbances of thyroid function and chronic diseases such
as heart failure, chronic renal failure and lung cancer. All
the above mentioned conditions are reported by several
studies to affect serum leptin, adiponectin and CRP levels
and could have a confounding effect regarding our results
[23–28]. Healthy registrars and consultants employed at
“Sotiria General Chest Hospital” were recruited as controls.
The subjects included in the control group were life-
long non-smokers. The exclusion criteria were the
same as the ones applied for the sample group. The
enrolment of the sample group took place from
September 2011 until December 2012. The controls
were recruited at the same time as the sample group.
All the participants signed a consent form. Our study
was approved by the Ethics Committee of University
of Larissa and our institution.
Intervention and measurements
Baseline characteristics of all patients were recorded
prior to commencing the smoking cessation program
(Table 1). Nicotine dependence was measured via the
eight-item Fagerstrom Tolerance Questionnaire [29].
Cumulative smoking exposure was determined in terms
of pack-years by multiplying the number of years
smoked with the average number of packs per day .
The patients had the option of a pharmacological approach
or a non-pharmacological approach to quit smoking. The
patients who decided to take pharmaceutical aid were
administered bupropion or varenicline as anti-smoking
drugs according to their medical history and nicotine
dependence.
The subjects who successfully quit smoking within the
time limits of our study constituted the sample group and
healthy non-smokers constituted the control group. Suc-
cessful cessation was confirmed by an exhaled carbon mon-
oxide level below 8 ppb, a cut-off providing 90 % sensitivity
and specificity for detecting tobacco use [30]. Blood sam-
ples were obtained in the morning following an overnight
fasting for determination of serum adiponectin, leptin and
CRP before study entry and at 3,6 months after smoking
cessation. The blood samples were collected at the same
time in the morning both for samples and controls at each
visit and then stored at −80 °C until biochemical assay.
Serum concentration of leptin and adiponectin were
measured by a commercially available sandwich enzyme-
linked immunosorbent assay (ELISA, Raybiotec Inc.) with
detection limit 7.8 pg/mL for leptin and 0.246 ng/mL for
adiponectin. Serum CRP was measured by high-sensitivity
CRP assay. Body mass index was also calculated before
study entry and at the end of month 3 and 6.
Statistical analysis
We performed power analysis using as reference values the
levels of leptin and adiponectin reported by several studies
in smokers, ex-smokers and non-smokers [31, 32]. A sam-
ple size of ≥32 subjects was calculated to be adequate for
detecting half of a standard deviation (1.5 mg/L) of basal
Table 1 Samples’ characteristics at baseline and 3 months and
6 months after smoking cessation
Participants’ characteristics Baseline 3 months 6 months
Age (years)a 56.1 ± 9.4 – –
Female sexa 16 (45.7) – –
BMI (kg/m2) 27.1 ± 3.7 28.6 ± 3.6* 29.2 ± 3.5*,**
Smoking (pack-years)a 54.3 ± 26.7 – –
Exhaled CO 14.7 ± 9.4 4.3 ± 2.5* 4.0 ± 2.7*
Serum leptin (ng/ml) 6.9 ± 3.1 10.5 ± 6.8* 6.5 ± 5.2**
Serum adiponectin (μg/ml) 9.5 ± 2.8 11.8 ± 5.5* 9.6 ± 5.2
CRP (mg/dl) 0.8 ± 1.1 0.3 ± 0.3* 0.3 ± 0.3*
Data are expressed as number of subjects (%) or mean value ± standard
deviation. Differences not marked with one of the above symbols are
not significant
*p < 0.05 vs. baseline
**p < 0.05 vs. 3 months
aAssessment applicable only at baseline
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leptin and adiponectin with a power 80 % at a significance
level of 5 % via two-tailed tests. A starting number of par-
ticipants of ≥160 was calculated on the assumption that
20 % of the participants manage to quit.
The Pearson correlation coefficient was used to describe
the relationships between variables. The Student’s t test
for continuous paired & unpaired data was used for intra
and inters group comparisons. The correlation-coefficient
p-values where calculated based on the Pearson’s product
moment correlation coefficient. Multiple regression ana-
lysis was performed using a Generalized Linear Model.
Model selection for the multiple regression analysis was
performed by utilizing a bi-directional stepwise algorithm.
Results
One hundred sixty eight apparently healthy smokers of
both sexes were recruited. Adequate follow up data were
available for 162 individuals. Among the 162 enrolled sub-
jects, 36 individuals successfully quit smoking for 3 months
and 29 of them reached 6 months of smoking cessation.
Four of the subjects who successfully quit smoking for
6 months did not visit the clinic for their first evaluation at
3 months, so data were available only for 32 individuals at
3 months. Only data from the subjects who successfully
quit smoking were analyzed. Ten individuals used vareni-
cline and 22 stopped smoking without pharmaceutical aid.
Three individuals completed the study after discontinuing
varenicline . The median interval between study entry and
actual quitting time was 6 days (range 2–22 days). The
measurement of exhaled carbon monoxide levels was per-
formed after a median interval of 92 days (range 85–98
days). The control group included 26 healthy non-smokers.
Samples’ leptin increased significantly from baseline to
three months of abstinence from smoking (mean change
3.76 ng/ml [95 % CI 0.89, 6.64], p = 0.012, Table 1). A statis-
tically significant decline in samples’ leptin was observed
from three to six months of smoking cessation (mean
change −4.29 ng/ml [95 % CI −7.34, −6.64], p = 0.008,
Table 1). Although serum leptin levels decreased from base-
line to 6 months of abstinence from smoking, this decline
was not statistically significant (p > 0.05). Controls’ leptin
did not change from baseline to six months (p > 0.05,
Table 2).
Samples’ adiponectin increased significantly from base-
line to three months after smoking cessation (mean
change 2.34 μg/ml [95 % CI −0.05, 4.73], p = 0.05, Table 1).
From three to six months of abstinence from smoking adi-
ponectin levels decreased (p > 0.05). Serum adiponectin
levels increased from baseline to six months of smoking
cessation but this rise did not reach statistically significant
levels. Controls’ adiponectin changes from baseline to six
months were not significant (p > 0.05, Table 2).
Samples’ BMI increased significantly from baseline to
6 months after quitting smoking (mean change 2.03 kg/m2
[95 % CI 1.60, 2.46], p = 2.7E-010, Table 1), whereas con-
trols’ BMI did not change from baseline (p > 0.05, Table 2).
Following smoking cessation, BMI increased at 3 months
(mean change 1.45 kg/m2 [95 % CI 1.18, 1.72], p = 5.71E-
012) and this increase remained significant from 3 to
6 months in the sample group (mean change 0.55 kg/m2
[95 % CI 0.12, 0.97], p = 0.014).
CRP decreased significantly from baseline to 3 months
(mean change −0.54 mg/dl [95 % CI −0.95, −0.14], p = 0.01,
Table 1) and from baseline to 6 months of abstinence from
smoking (mean change −0.68 mg/dl [95 % CI −1.06, −0.30],
p = 0.001, Table 1). The controls’ CRP levels remained
stable (p > 0.05, Table 2).
Intra-individual changes of leptin and adiponectin are
illustrated in Fig. 1 and Fig. 2.
Tables 3 and 4 demonstrate linear relationships between
adiponectin and leptin and participants’ characteristics in
the overall population at month 6. There was a strong
positive association between age and adiponectin, while
leptin exhibited a negative correlation with age.
We performed multiple regression analysis to examine
whether leptin and adiponectin levels variation could be
explained by specific independent predictors of leptin and
adiponectin including age, gender, BMI and smoking
(Tables 5 and 6). A multiple regression model including the
difference of leptin levels between baseline and third
month, the gender and the log-transformed age parameter
explained ~66 % of the adiponectin levels variation at
6 months (adjusted R2 = 0.66). The analysis also produced a
statistically significant model for leptin at 6 months
containing only the difference of adiponectin levels between
baseline and the third month which explained 16 % of
leptin levels variation (adjusted R2 = 0.16).
Discussion
Our study showed smoking quitters’ leptin levels to in-
crease significantly 3 months after smoking cessation
and then decrease significantly from 3 to 6 months of
Table 2 Controls’ characteristics at baseline and after 6 months
Participants’ characteristics Baseline 6 months
Age (years)a 33.7 ± 6.0 –
Female sexa 22 (84.6) –
BMI (kg/m2) 23.1 ± 5.1 23.2 ± 5.1
Smoking (pack-years)a 54.3 ± 26.7 –
Exhaled CO 3.5 ± 2.2 3.7 ± 1.9
Serum leptin (ng/ml) 2.1 ± 1.4 2.1 ± 1.4
Serum adiponectin (μg/ml) 1.5 ± 1.3 1.5 ± 1.2
CRP (mg/dl) 0.06 ± 0.06 0.05 ± 0.05
Data are expressed as number of subjects (%) or mean value ± standard
deviation. Differences not marked with one of the above symbols are
not significant
aAssessment applicable only at baseline
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abstinence from smoking. Adiponectin levels increased
significantly during the first trimester of smoking cessa-
tion. These alterations of serum leptin and adiponectin
concentration occurred along with a significant increase
in BMI and a significant decrease in CRP levels after
6 months of abstinence from smoking.
Only a few studies addressed the impact of quitting
smoking on leptin concentration. Eliasson and Smith
suggested that the leptin levels would increase 8 weeks
after smoking cessation [17]. Perkin and Fonte also
reported that the leptin levels increased, particularly in
female smokers 3 weeks after nicotine abstinence [18].
However, Nicklas et al. suggested that the changes
observed in leptin concentration in 13 patients after
6 months of smoking cessation were not significant [19].
A significant increase in serum leptin levels one year
after smoking cessation was reported in a recent study
by Gonseth et al. [22].
The elevated plasma leptin concentration observed in
smokers may be due to an increase in adipose tissue
secretion of leptin or a decrease in leptin clearance.
Previous studies report that nicotine increases adipose
tissue lipolysis [33, 34], and smokers have elevated fast-
ing adipose tissue lipoprotein lipase activity [35, 36].
Fig. 1 Scatterplot of samples and controls’ leptin at baseline and after smoking cessation
Fig. 2 Scatterplot of samples’ and controls’ adiponectin at baseline and after smoking cessation
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Cigarette smoking enhances the adrenal release of gluco-
corticoids [37], which elevate plasma leptin concentrations
by increasing leptin expression in adipose tissue [38].
In our study the increased leptin levels 3 months after
smoking cessation occurred after a preceding increase in
body weight and may reflect the increase in body fat
after smoking cessation. The fact that leptin initially
increases may imply that leptin was influenced by the
increase in body weight predominantly the first trimester
of smoking cessation. From 3 to 6 months of abstinence
from smoking, leptin levels decrease despite weight gain.
If we consider the role of leptin in the recruitment, acti-
vation and survival of inflammatory cells we can assume
that this decline in leptin levels indicates that the low
grade subclinical inflammation observed in smokers is
gradually restored after smoking cessation.
In contrast to the findings that weight reduction is
associated with an increase in adiponectin concentration
[13, 39] we demonstrated that serum adiponectin concen-
tration increased three months after smoking cessation
despite of weight gain. This is in line with several previous
studies [20, 21]. Otsuka et al. reported that plasma adipo-
nectin levels in Japanese patients were elevated 6 months
after smoking cessation [20]. Efstathiou et al. also demon-
strated that adiponectin levels in Greek smokers increased
9 weeks after nicotine abstinence [21].
Several explanations have been proposed for the mecha-
nisms by which smoking cessation modulates adiponectin
expression and secretion. Smoking provokes oxidative
stress and inflammatory cytokines that reduce the expres-
sion and secretion of adiponectin [40]. Nicotine itself
induces lipolysis and may suppress adiponectin gene
expression [40, 41]. Adiponectin accumulates in the injured
vascular walls of smokers. Therefore, the increased con-
sumption of circulating adiponectin might represent
another mechanism causing lower levels of adiponectin in
smokers [42].
Both smoking and body weight affect adiponectin
levels. During the first trimester of smoking cessation
adiponectin levels increased significantly in the sample
group despite weight gain. Although adiponectin levels
finally increase from baseline to 6 months of abstinence
from smoking, this increase does not reach statistically
significant levels. It is possible that during the second
trimester of smoking cessation the adiponectin decreas-
ing effect of weight gain towers above the adiponectin
increasing effect of smoking cessation.
BMI increased significantly during the period of abstin-
ence in this study. It is well proven that cigarette smoking
is associated with lower body weight. Cross-sectional
studies show that smokers weigh less than age-matched
non-smokers, while longitudinal data show that most
smokers gain weight after smoking cessation [35, 43, 44].
Several studies reported that smoking cessation reversed
the increased energy expenditure in smokers, and the
BMI of the quitters increased [18, 44, 45]. However, the
specific mechanisms by which smoking affects body
weight are not completely clear. It has been reported that
weight gain is a result of increased food consumption and
decreased energy expenditure upon cessation of smoking
[46–49]. Smoking increases the adrenergic activity, which
can directly increase thermogenesis and reduce weight.
In addition, it seems that nicotine has a direct effect
on adipose tissue metabolism during smoking which
influences the rate of weight gain after smoking cessation
[33, 35, 36].
Table 3 Linear relationships between adiponectin and
participants’ characteristics in the total population at month 6
Variable Correlation coefficient r p value
Agea 0.589 <0.001
Gender (male = 1, female = 2)a 0.320 0.097
Smoking (pack/years)a 0.142 0.470
Exhaled Carbon Monoxidea −0.328 0.089




Table 4 Linear relationships between leptin and participants’
characteristics in the total population at month 6
Variable Correlation coefficient r p value
Agea −0.374 0.050
Gender (male = 1, female = 2)a −0.303 0.117
Smoking (pack/years)a −0.173 0.378
Exhaled Carbon Monoxidea 0.146 0.457




Table 5 Independent predictors of adiponectin levels in the
total population at month 6
Variable Standardized β coefficient Standard error p value
Leptin 0 - Leptin 3a −0.025 0.012 0.042
Gender 0.526 0.138 0.001
Log (Age) 3.095 0.480 <0.001
aDifference of leptin levels at 3 months from leptin levels at baseline
Table 6 Independent predictors of leptin levels in the total
population at month 6
Variable Standardized β coefficient Standard error p value
Adiponectin
0 - Adiponectin 3a
−0.025 0.012 0.042
aDifference of adiponectin levels at 3 months from adiponectin levels at baseline
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We did not detect a positive or a negative correlation of
leptin or adiponectin with BMI. A possible explanation is
that changes in leptin and adiponectin are associated with
changes in fat distribution after smoking cessation. The
degree of obesity as measured by BMI may not reflect the
amount and distribution of adipose tissue.
Similar to previous reports, CRP plasma levels decreased
significantly from baseline to 6 months after smoking cessa-
tion [50]. Most studies that have examined CRP status in
former smokers suggest that levels fail to fall immediately
upon cessation, which reflects the fact that the underlying
tissue damage caused by smoking takes some time to
recover [50]. CRP is a well known marker of subclinical
inflammation and therefore the decrease in CRP levels
observed in our study indicates that low grade inflamma-
tion is gradually restored after smoking cessation.
Multivariate analysis revealed an interesting association
between leptin and adiponectin. It appears that the differ-
ence of either one of these two adipokines from baseline to
3 months of smoking abstinence is predictive for the levels
of the other adipokine 6 months after smoking cessation. It
is likely that leptin and adiponectin act via several interre-
lated metabolic pathways. Smoking seems to change the
balance between these two adipokines causing effects on
inflammatory processes and insulin resistance that may
contribute to the pathogenesis of cardiovascular disease
[12, 51–53].
Several methodological aspects of our study require
consideration. Although quitters’ exhaled CO levels were
compatible with moderate exposure to environmental to-
bacco smoke this could not elucidate the effects of passive
smoking on serum leptin and adiponectin levels. Further-
more, the possibility of any direct impact of varenicline on
serum leptin and adiponectin levels could not be ex-
cluded. Although the BMI is a reasonable measure of adi-
posity, it may not always precisely reflect the quantity of
body fat [20]. The present findings could be altered if the
amount and distribution of adipose tissue were obtained
by measuring waist and hip circumference or other mea-
sures of total and abdominal adiposity in place of BMI.
Another limitation of the study is not measuring triglycer-
ides and HDL-cholesterol that could independently modu-
late leptin and adiponectin levels [54]. Having in mind that
hypadiponectinemia in overweight individuals and in type
II diabetic patients is closely associated with insulin resist-
ance and hyperinsulinemia [55], we excluded subjects with
type II diabetes and severe obesity. Nevertheless, the lack of
insulin data must be considered a limitation of our study
since it has been suggested recently that insulin may be
involved in the association of smoking and leptin [22].
Further research on this subject is needed.
Previous reports showed that smoking-related damage
via low grade inflammation and endothelial dysfunction
may persist after smoking cessation and continue to
influence leptin and adiponectin levels [56]. Thus, larger
and durable cohort studies are required to assess whether
the alterations observed in serum leptin and adiponectin
concentration after abstinence from smoking exert a pro-
tective effect against cardiovascular disease and metabolic
diseases.
Conclusions
Smoking quitters’ leptin levels appear to increase 3 months
after smoking cessation and then decrease from 3 to
6 months of abstinence from smoking. Adiponectin levels
increase during the first trimester of smoking cessation.
The decrease in CRP levels indicates that the low grade
inflammation observed in smokers is gradually restored.
The alterations of serum leptin and adiponectin after
6 months of smoking cessation suggest the same but do
not reach statistically significant levels. Weight gain and
changes in fat distribution may attenuate the beneficial
effects of smoking cessation.
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